Gland Pharma Limited (GLAND) — Cash Flow-to-Debt Ratio
Gland Pharma Limited (GLAND) has a Cash Flow-to-Debt Ratio of 0.27x as of September 2025, meaning its operating cash flow of Rs5.93 Billion could theoretically repay 0% of its total liabilities (Rs22.37 Billion) in one year. See GLAND free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Gland Pharma Limited Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Gland Pharma Limited across 9 annual periods. Also explore Gland Pharma Limited net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Gland Pharma Limited (2017–2025)
Year-by-year debt coverage analysis for Gland Pharma Limited. For market capitalisation and broader financial context, see GLAND stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (INR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.44x | Rs9.15 Billion | Rs20.74 Billion | ▼ -14.3% |
| 2024 | 0.51x | Rs9.97 Billion | Rs19.37 Billion | ▲ +15.7% |
| 2023 | 0.44x | Rs3.64 Billion | Rs8.19 Billion | ▼ -62.0% |
| 2022 | 1.17x | Rs7.91 Billion | Rs6.76 Billion | ▲ +14.6% |
| 2021 | 1.02x | Rs6.05 Billion | Rs5.93 Billion | ▼ -36.0% |
| 2020 | 1.59x | Rs7.01 Billion | Rs4.40 Billion | ▲ +469.1% |
| 2019 | 0.28x | Rs1.85 Billion | Rs6.62 Billion | ▼ -28.1% |
| 2018 | 0.39x | Rs2.02 Billion | Rs5.19 Billion | ▼ -68.6% |
| 2017 | 1.24x | Rs4.76 Billion | Rs3.84 Billion | — |